Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take on tough ovarian cancer in first human trial

NCT ID NCT07030907

Recruiting now Disease control Sponsor: Outpace Bio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a one-time treatment called OPB-101 for women with ovarian cancer that no longer responds to platinum chemotherapy. The therapy uses a patient's own immune cells (T cells) that are modified in a lab to better recognize and attack cancer cells, plus a built-in boost to help them work longer. The main goals are to check safety and find the right dose in 30 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
OPB-101 (a CAR T cell therapy made from the patient's own immune cells, engineered to target mesothelin and produce IL-2)
What this could lead to
If successful, this could point toward a new treatment option for women with hard-to-treat ovarian cancer that has stopped responding to standard chemotherapy.
What could go wrong
This is a very early (Phase 1) and small (30 people) trial focused mainly on safety. The therapy may not shrink tumors or may cause serious side effects. It is not a cure and requires ongoing monitoring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER OVARIAN CANCER RECURRENT PLATINUM-RESISTANT OVARIAN CANCER

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Karmanos Cancer Institute

    RECRUITING

    Detroit, Michigan, 48201, United States

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • Roswell Park

    RECRUITING

    Buffalo, New York, 14203, United States

  • University of Minnesota

    RECRUITING

    Minneapolis, Minnesota, 55455, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.